Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
BMC Cancer|July 4, 2012
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysisDimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, et al.
BMC Cancer|February 5, 2013
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypesGeorge Pentheroudakis, Vassiliki Kotoula, Wendy De Roock, et al.
ESMO Open|June 25, 2019
Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancerElena Fountzilas, Vassiliki Kotoula, George Pentheroudakis, et al.
Anticancer Research|April 7, 2019
Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal CancerGrigorios Rallis, Triantafyllia Koletsa, Zenia Saridaki, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2014
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximabEvangelia Razis, George Pentheroudakis, George Rigakos, et al.
Therapeutic Advances in Medical Oncology|September 15, 2022
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre studyFoteinos-Ioannis Dimitrakopoulos, Giannis Mountzios, Petros Christopoulos, et al.
Annals of Gastroenterology|January 12, 2016
Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMOPanteleimon Kountourakis, John Souglakos, Nikolaos Gouvas, et al.
BMC Medicine|February 2, 2011
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group studyChristos A Papadimitriou, Pavlos Papakostas, Maria Karina, et al.
Annals of Gastroenterology|January 12, 2016
Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMOEvaghelos Xynos, Nikolaos Gouvas, Charina Triantopoulou, et al.
Oncotarget|February 1, 2020
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine InitiativeElena Fountzilas, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.
Pageof 11